New Enrichment Media Formats Offer Reduced Preparation Time to Food Microbiology Laboratories

Thermo_Fisher_Scientific_Logo Thermo Fisher Scientific QuickBag, 4.5L Thermo Fisher Scientific FitBag 4.5L Help streamline media preparation workflows and increase productivity BASINGSTOKE, England, June 27, 2017 /PRNewswire/ — To facilitate operational efficiency in food microbiology laboratories, a new range of bagged enrichment media is designed to reduce hands-on preparation time. The bags contain pre-weighed, ready-to-hydrate, gamma-irradiated enrichment media... Read more

Roka Bioscience to Co-Present Industry Webinar

WARREN, N.J., June 26, 2017 /PRNewswire/ — Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens will host and present, along with Primus Laboratories, an informative webcast titled “Food Safety Pixels to Pictures: How to Bring your Data to Life“. This webcast topics will... Read more

Bruker Announces Novel NMR Phenomics Research Capabilities

BRISBANE, Australia, June 26, 2017 /PRNewswire/ — At the Metabolomics Society Meeting 2017, Bruker announces a new solution for the quantification of metabolites in urine using Nuclear Magnetic Resonance (NMR). Urine metabolic analysis is particularly valuable and information-rich, because the metabolic pathways of a wide range of nutrients, drugs and environmental contaminants can be identified in urine,... Read more

Greiner Bio-One North America, Inc. Announces Contract Renewal with Vizient, Inc.

Greiner Bio-One North America, Inc. is proud to announce an extension of the supplier agreement between Greiner Bio-One North America, Inc. and Vizient, Inc., the largest member-driven health care performance improvement company in the country. This new contract continues a long standing and successful relationship between the two organizations for high-quality phlebotomy products now extending... Read more

Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ:ILMN) and Genomics England announced today that Illumina is the primary variant interpretation and reporting software vendor for tumor and matched normal samples characterized as part of the 100,000 Genomes Project. In a little over a year since Illumina announced the Bioinformatics and Clinical Interpretation Partnership with Genomics England, the partnership has now set... Read more

Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more

Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors

Basel, 26 June 2017 Roche’s emicizumab showed positive results in phase III studies (HAVEN 1 and HAVEN 2) in haemophilia A with inhibitors Emicizumab showed substantial and clinically meaningful reduction in bleeds across two pivotal studies Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children to be presented... Read more